Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology.
about
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)Aripiprazole and Acute Extrapyramidal Symptoms in Children and Adolescents: A Meta-AnalysisLack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autismHow experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral interaction trialsWorking towards consensus on methods used to elicit participant-reported safety data in uncomplicated malaria clinical drug studies: a Delphi technique study.Improving reporting of adverse drug reactions: Systematic review.Aripiprazole in children and adolescents with Tourette's disorder: an open-label safety and tolerability studyTesting tic suppression: comparing the effects of dexmethylphenidate to no medication in children and adolescents with attention-deficit/hyperactivity disorder and Tourette's disorderYokukansan (TJ-54) for treatment of pervasive developmental disorder not otherwise specified and Asperger's disorder: a 12-week prospective, open-label study.The Food and Drug Administration's deliberations on antidepressant use in pediatric patients.Child/Adolescent anxiety multimodal study: evaluating safety.Treatment for Adolescents with Depression Study (TADS): safety resultsPost-acute effectiveness of lithium in pediatric bipolar I disorder.The Collaborative Lithium Trials (CoLT): specific aims, methods, and implementationReports of Perceived Adverse Events of Stimulant Medication on Cognition, Motivation, and Mood: Qualitative Investigation and the Generation of Items for the Medication and Cognition Rating Scale.Advances in the treatment of pediatric obsessive-compulsive d-cycloserine with exposure and response prevention.Psychotropic medication monitoring checklists: use and utility for children in residential care.Side effects from use of one or more psychiatric medications in a population-based sample of children and adolescents.SENTIA: a systematic online monitoring registry for children and adolescents treated with antipsychotics.A Review of the Safety, Efficacy and Mechanisms of Delivery of Nasal Oxytocin in Children: Therapeutic Potential for Autism and Prader-Willi Syndrome, and Recommendations for Future Research.Emotional well-being in children and adolescents treated with atomoxetine for attention-deficit/hyperactivity disorder: findings from a patient, parent and physician perspective using items from the pediatric adverse event rating scale (PAERS).A randomized, placebo controlled trial of omega-3 fatty acids in the treatment of young children with autism.Aripiprazole in juvenile bipolar disorder comorbid with attention-deficit/hyperactivity disorder: an open clinical trial.ABCB1 polymorphisms and neuropsychiatric adverse events in oseltamivir-treated children during influenza H1N1/09 pandemia.A Review of Methods for Monitoring Adverse Events in Pediatric Psychopharmacology Clinical Trials.Study protocol for a single-blind, randomised controlled, non-inferiority trial of internet-based versus face-to-face cognitive behaviour therapy for obsessive-compulsive disorder
P2860
Q24200368-E2054313-9B1D-4ADE-AE37-E2BBE8A47553Q24236316-245FC018-98E8-465D-816A-285445F5132AQ28073540-10303288-534B-48BF-8874-90B579D0322CQ28247116-4B7CE100-3496-4787-B9A7-EA31EEC41219Q30557423-1F28F0B9-DEA8-4296-BE90-70AA0328A9C7Q30836732-039622B5-BAAB-4DE8-8937-A93065479698Q33701650-8301AFB4-FF9F-497A-BCD1-36451F7B4865Q33819964-B91C0B7A-8D18-4E7E-8BD2-262E5768BD0FQ34218754-302FFB30-A180-45BA-8C94-C51734DD23E9Q34495483-18ADEB42-7ACF-4D60-A0F8-FDEDE64A47CCQ34998784-635C7147-E6DB-4104-A898-91C7A1CE9024Q35185333-6B744AA7-9C20-4502-816A-AF319C78F7CBQ35773690-73F8D1F7-DBE8-4588-A381-58903FA6170AQ36720669-5E37EC72-756A-44C2-94E8-BBD03D859509Q36865365-D71DA2D0-2A5F-47F9-A60A-A6EF69EA56CEQ37190637-ECCAEB29-AB5F-443A-AE50-C003BF526C4FQ37257029-D9D4FEF6-3484-4B53-B789-098F3ED05558Q37567443-D83A2BBE-F36A-4A95-AA2B-D30BDE116311Q37667578-230691B0-9190-42E5-8752-C06B926E624CQ37724890-FB797D39-FED9-4209-A400-031483306897Q38655523-5FB01CDA-C8B0-445F-9821-9F3EF49B7E39Q39244282-AD4387A1-7B7F-4575-AFFF-B09C51D5582EQ43196014-000F4A71-F8FB-43A7-B436-9E1CDE3122DFQ46952830-2FD7FA4D-DC00-408C-B08F-D7BA94289B29Q48910582-8E371BCD-FAED-4F7C-8325-A7D2480D125CQ50109827-03939D90-609E-4F7C-8381-E1548CD6E318Q58763103-D4F49E9C-269B-4952-AD6E-77DCBCCEDA06
P2860
Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Comparison of increasingly det ...... pediatric psychopharmacology.
@ast
Comparison of increasingly det ...... pediatric psychopharmacology.
@en
type
label
Comparison of increasingly det ...... pediatric psychopharmacology.
@ast
Comparison of increasingly det ...... pediatric psychopharmacology.
@en
prefLabel
Comparison of increasingly det ...... pediatric psychopharmacology.
@ast
Comparison of increasingly det ...... pediatric psychopharmacology.
@en
P2093
P1476
Comparison of increasingly det ...... pediatric psychopharmacology.
@en
P2093
Allan K Chrisman
Benedetto Vitiello
Howard Abikoff
Jerome Levine
John March
John Walkup
Laurence L Greenhill
Mark A Riddle
Mark Davies
Prudence Fisher
P304
P356
10.1097/01.CHI.0000142668.29191.13
P577
2004-12-01T00:00:00Z